The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant: A cost-effectiveness analysis updated with 5-year follow-up data from the pivotal trial.
 
Christopher Parker
Employment - ICON Clinical Research
Stock and Other Ownership Interests - ICON Clinical Research
Consulting or Advisory Role - ICON Clinical Research; Takeda
Travel, Accommodations, Expenses - Takeda
 
Gemma Kay
Employment - ICON Clinical Research
Consulting or Advisory Role - ICON Clinical Research; Takeda
Travel, Accommodations, Expenses - ICON Clinical Research; Takeda
 
Esprit Ma
Employment - Millennium
Stock and Other Ownership Interests - Takeda
 
Beth Woods
No Relationships to Disclose
 
James Eaton
Employment - ICON Clinical Research
 
Peter Sajosi
Employment - Takeda
Travel, Accommodations, Expenses - Takeda
 
Andreas Engstrom
Employment - Takeda
 
Ross Selby
Employment - Takeda
 
Eugene Benson
Employment - Takeda
 
Jeremy Teasell
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Research Funding - Seagen (Inst)
Travel, Accommodations, Expenses - Seagen
 
Akshara Richhariya
Employment - Seagen
Stock and Other Ownership Interests - Amgen; Seagen
 
Andrew Briggs
Employment - ICON Clinical Research
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Millennium; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Millennium; Sanofi
 
Vijayveer Bonthapally
Employment - Millennium
Stock and Other Ownership Interests - Takeda